Determination of gelatinase A using a modified indirect hemagglutination assay in human prostate cancer screening and assessment of its correlation with prostate-specific antigen parameters

International Journal of Urology

Volumn 12, Issue 7, 2005, Pages 637-643

  Khorramizadeh, Mohammad Reza ^a   Aalizadeh, Nastaran ^b   Pezeshki, Mohammad ^a   Ghahary, Aziz ^c   Zeraati, Hojat ^a   Berahmeh, Azar ^a   Safa, Omid ^b   Saadat, Farshid ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Gelatinase A; IHA; PSA; Zymography

Indexed keywords

GELATINASE A; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DENSITOMETRY; DRUG ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; ZYMOGRAPHY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; HEMAGGLUTINATION TESTS; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC DISEASES; PROSTATIC NEOPLASMS;

EID: 28444486500     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2005.01094.x     Document Type: Article

References (29)

1. Crawford ED. Epidemiology of prostate cancer. Urology 2003; 62: 3-12.
2. Woessner FJ Jr. Matrix Metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991; 5: 2145-50.
3. Woessner FJ. Matrix Metalloproteinases and Timps, 1st edn. Oxford University Press, Oxford, UK, 2000.
4. Massova I, Kotra LP. Matrix metalloproteinases: structures, evaluation, diversitification. FASEB J. 1998; 12: 1075-95.
5. Khorramizadeh MR, Tredget EE, Telasky C, Shen Q, Ghahary A. Aging differentially modulates the expression of collagene and collagenase in dermal fibroblasts. Mol. Cell. Biochem. 1999; 194: 99-108.
6. Telasky C, Tredget EE, Shen Q et al. IFN-α2b suppresses the fibrogenic effects of insulin-like growth factor-1 in dermal fibroblasts. J. Interferon Cytokine Res. 1998; 18: 571-7.
7. Saadat F, Zomorodian K, Pezeshki M, Safavifar F, Khorramizadeh MR. Comparative analysis of potential inhibitory effects of non-steroidal anti-inflammatory drugs (NSAIDs) on cancer cell model. PJMS 2003; 19: 13-17.
8. Davies B, Waxman J, Wasan H. Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 1993; 53: 5365-9.
9. Deryugina EL, Luo GX, Reisfeld RA, Strongin A. Tumor cell invasion through matrigel is regulated by activated MMP-2. Anticancer Res. 1997; 17: 3201-10.
10. Cockett MI, Murphy G, Birch ML. Matrix metalloproteinases and metastatic cancer. Biochem. Soc. Symp. 1998; 63: 295-313.
11. Endo K, Maehara Y, Baba H et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res. 1997; 17: 2253-8.
12. Ratnikov B, Deryugina E, Eng J, Marchenko G, Dembrow D, Strongin A. Determination of matrix metalloproteinase activity using biotinylated gelatine. Anal Biochem. 2000; 286: 149-55.
13. Wilson MJ, Sellers RG, Wiehr C, Melamud O, Pei D, Peehl DM. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. J. Cell. Physiol. 2002; 191: 208-16.
14. Moses MA, Wiederchain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998; 58: 1395-9.
15. Zucker S, Hymowil M, Conner C et al. Measurement of matrix metalloproteinases and tissue inhibitors of met-alloproteinases in blood and tissues. Clinical and experimental application. Ann. N. Y. Acad. Sci. 1999; 676: 212-27.
16. David E, Kleiner, William G, Stetler Stevenson WG. Quantitative Zymography: detection of pictogram quantities of gelatinase. Anal. Biochem. 1994; 218: 325-9.
17. Saadat F, Zomorodian K, Pezeshki M, Rezaie S, Khorramizadeh MR. Inhibitory effect of Aspergillus fumigatus extract on matrix metalloproteinases expression. Mycopathologia 2004; 158: 33-7.
18. Hudson L, Hay F. Practical Immunology, 3rd edn. Blackwell Scientific Publication, Oxford, UK, 1991; 252-7.
19. Horninger W, Cheli CD, Babaian RJ et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2-4 nanograms per minutes. Uorology 2002; 60 (4 suppl. 1): 31-5.
20. Morote J, Trilla E, Esquena S et al. Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer. Int. J. Biol. Markers 2002; 17: 239-43.
21. Epstein JI, Walsh PC, Carmichael M. Pathologic and clinical finding to predict tumor extent in non-palpable (Tlc) prostate cancer. JAMA 1994; 271: 368-74.
22. Scaletsky R, Koch MO, Eckstein CW. Tumor volume and stage in carcinomas of the prostate detected by elevations of prostate specific antigen. J. Urol. 1994; 152: 129-31.
23. Hamdy FC, Fadlon EJ, Cottam D et al. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer 1994; 69: 177-82.
24. 2V colagenase (Matrix metalloproteinase-9 and -2) activities by transforming growth factor-β1 in human prostate cancer cell lines. Mol. Biol. Cell 1999; 10: 407-16.
25. Varani J, Hattori Y, Dame MK et al. Matrix metalloproteinases (MMPs) in fresh human prostate tumor tissue and organ-cultured prostate tissue: levels of collagenolytic and gelatinolytic MMPs are low, variable and different in fresh tissue versus organ-cultured tissue. Br. J. Cancer 2001; 84: 1076-83.
26. Gray WO, Leferson JD, Stetler Stevenson WG, Kleiner DE. Quantitative reverse zymography: analysis of picogram amounts metalloproteinase inhibitors using gelatinase A and B reverse zymograms. Anal. Biochem. 1997; 244: 161-6.
27. Gohji K, Fujimoto N, Hara I et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extention. Int. J. Cancer 1998; 79: 96-101.
28. Bannikov GA, Karelina TV, Collier IE, Marmer BL, Goldberg GI. Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J. Biol. Chem. 1994; 277: 16022-7.
29. McGeehan GM, Bickett DM, Green M, Kassel D, Wiseman JS, Berman J. Characterization of the peptide substrate specificities of interstitial collagenase and 92-kDa gelatinase. Implications for substrate optimization. J. Biol. Chem. 1994; 269: 32814-20.